Literature DB >> 12393505

von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.

Reinhard Schneppenheim1, Ulrich Budde, Florian Oyen, Dorothea Angerhaus, Volker Aumann, Elke Drewke, Wolf Hassenpflug, Johannes Häberle, Karim Kentouche, Elisabeth Kohne, Karin Kurnik, Dirk Mueller-Wiefel, Tobias Obser, René Santer, Karl-Walter Sykora.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is caused by the persistence of the highly reactive high-molecular-weight multimers of von Willebrand factor (VWF) due to deficiency of the specific VWF-cleaving protease (VWF-CP) ADAMTS13, resulting in microangiopathic disease. The acquired form is caused by autoantibodies against VWF-CP, whereas homozygous or compound heterozygous mutations of ADAMTS13 are responsible for recessively inherited TTP. We investigated 83 children with hemolytic or thrombocytopenic episodes with or without additional neurologic symptoms or renal failure. The presumed diagnosis was chronic idiopathic thrombocytopenic purpura (ITP; n = 50), TTP (n = 8), hemolytic uremic syndrome (HUS; n = 24), and Evans syndrome (n = 1). A severe deficiency of VWF-CP (< or = 5%) was found in all investigated patients with TTP and in none of those with HUS. Additionally, 2 of 50 patients with a prior diagnosis of ITP were deficient for VWF-CP. Antibodies against VWF-CP were found in 4 children. Mutation analysis of the ADAMTS13 gene in the patients deficient in VWF-CP by direct sequencing of all 29 exons identified 8 different mutations, suggesting the hereditary form of TTP in 1 patient with ITP, in the patient with Evans syndrome, and in 5 of the 8 patients with TTP. The phenotype of TTP in childhood can be rather variable. Besides the classical clinical picture, oligosymptomatic forms may occur that can delay the identification of patients at risk.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393505     DOI: 10.1182/blood-2002-08-2399

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

Review 2.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

3.  Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?

Authors:  Wenhua Zhou; Lingli Dong; David Ginsburg; Eric E Bouhassira; Han-Mou Tsai
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

4.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

Review 5.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

Review 6.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

7.  Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.

Authors:  Jeffrey J Sutherland; Lee A O'Brien; David Lillicrap; Donald F Weaver
Journal:  J Mol Model       Date:  2004-08-03       Impact factor: 1.810

Review 8.  Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

Review 9.  The kidney in thrombotic thrombocytopenic purpura.

Authors:  H-M Tsai
Journal:  Minerva Med       Date:  2007-12       Impact factor: 4.806

Review 10.  Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.

Authors:  Roslyn Yomtovian; Waldemar Niklinski; Bernard Silver; Ravindra Sarode; Han-Mou Tsai
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.